2.745
Immunitybio Inc stock is traded at $2.745, with a volume of 4.49M.
It is up +7.77% in the last 24 hours and down -0.18% over the past month.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
See More
Previous Close:
$2.51
Open:
$2.54
24h Volume:
4.49M
Relative Volume:
0.70
Market Cap:
$2.45B
Revenue:
$1.31M
Net Income/Loss:
$-597.65M
P/E Ratio:
-2.8299
EPS:
-0.97
Net Cash Flow:
$-425.62M
1W Performance:
-2.70%
1M Performance:
-0.18%
6M Performance:
-22.49%
1Y Performance:
-45.24%
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
IBRX
Immunitybio Inc
|
2.725 | 2.45B | 1.31M | -597.65M | -425.62M | -0.97 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
489.15 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
583.23 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
599.94 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
235.89 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
254.05 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-06-25 | Initiated | H.C. Wainwright | Buy |
Jan-10-25 | Initiated | BTIG Research | Buy |
May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
Aug-03-22 | Initiated | Jefferies | Buy |
Immunitybio Inc Stock (IBRX) Latest News
ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting - BioSpace
Why ImmunityBio, Inc. (IBRX) Declined on Wednesday - Yahoo Finance
Economic Uncertainties Batter Trading in These 10 Firms - Insider Monkey
ImmunityBio sees Q1 sales surge, submits FDA applications By Investing.com - Investing.com South Africa
ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia - BioSpace
ImmunityBio Completes FDA License Application Submissions - marketscreener.com
Immunitybio Announces FDA Submissions Of Supplemental BLA For Nmibc Papillary Disease And For Expanded Access Of Anktiva®To Treat Lymphopenia - marketscreener.com
ImmunityBio sees Q1 sales surge, submits FDA applications - Investing.com
Why ImmunityBio Inc. (IBRX) Skyrocketed On Monday? - MSN
Is ImmunityBio Stock Heading Upwards? - timothysykes.com
ImmunityBio settles securities class action lawsuit for $10.5 million - Claim Depot
ImmunityBio, Inc. (IBRX): Among Stocks Under $10 that Will Triple - Insider Monkey
Why ImmunityBio Inc. (IBRX) Went Down On Tuesday? - Insider Monkey
ImmunityBio secures $75 million in direct offering - Investing.com Australia
ImmunityBio secures $75 million in direct offering By Investing.com - Investing.com South Africa
SEC Form 424B5 filed by ImmunityBio Inc. - Quantisnow
ImmunityBio Stock: What’s Driving the Market? - timothysykes.com
Rallybio ends development in rare disorder; ImmunityBio raises $75M - Endpoints News
ImmunityBio Launches $75 Million Registered Direct Offering - MarketScreener
ImmunityBio (IBRX) Secures $75 Million in Direct Offering - GuruFocus
ImmunityBio raises $75 million in equity financing - MSN
ImmunityBio Secures $75 Million in Direct Offering - TipRanks
ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor - Business Wire
IMMUNITYBIO, INC. SHAREHOLDER ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against ImmunityBio, Inc. (NASDAQ: IBRX) - ACCESS Newswire
ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch - BioSpace
Investor Alert: Wolfspeed, Driven Brands Holdings, Hasbro, - GlobeNewswire
Investor Alert: Wolfspeed, Driven Brands Holdings, Hasbro, and ImmunityBio: Johnson Fistel, PLLP Investigates Claims on Behalf of Investors - TradingView
ImmunityBio: Taking Care Of Business (NASDAQ:IBRX) - Seeking Alpha
ImmunityBio and Beigene to run Phase 3 of Anktiva plus PD-1 in NSCLC - PPF Group
Why ImmunityBio Inc. (IBRX) Went Up Last Week? - Yahoo Finance
Is ImmunityBio, Inc. Stock a Buy Right Now? - timothysykes.com
ImmunityBio’s Recent Surge: What’s Behind It? - timothysykes.com
ImmunityBio to Host Investor Day - BioSpace
Is ImmunityBio, Inc. (NASDAQ:IBRX) The Top Penny Stock That Will Skyrocket? - Insider Monkey
Investor Alert: Wolfspeed, Driven Brands Holdings, Hasbro, and ImmunityBio: Johnson Fistel, PLLP Investigates - EIN News
ImmunityBio appoints Deloitte as new auditor By Investing.com - Investing.com South Africa
ImmunityBio appoints Deloitte as new auditor - Investing.com Australia
Drugmaker's $10.5M Deal In Investor FDA Approval Suit OK'd - Law360
ImmunityBio $10.5 Million Settlement Over Record Selloff Gets OK - Bloomberg Law News
From cancer vaccines to COPD treatments, these 10 companies are developing innovative medicines - Fast Company
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunitybio Inc Stock (IBRX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
SOON-SHIONG PATRICK | See remarks |
Feb 22 '25 |
Option Exercise |
0.00 |
114,329 |
0 |
29,588,261 |
Sachs David C. | Chief Financial Officer |
Feb 22 '25 |
Option Exercise |
0.00 |
40,650 |
0 |
241,480 |
Adcock Richard | CEO & President |
Feb 22 '25 |
Option Exercise |
0.00 |
152,439 |
0 |
412,585 |
Simon Barry J. | Director |
Feb 22 '25 |
Option Exercise |
0.00 |
15,243 |
0 |
3,249,024 |
Simon Barry J. | Director |
Jan 22 '25 |
Option Exercise |
2.00 |
110,020 |
219,864 |
3,233,781 |
Adcock Richard | CEO & President |
Dec 31 '24 |
Option Exercise |
0.00 |
34,483 |
0 |
277,621 |
Sachs David C. | Chief Financial Officer |
Dec 31 '24 |
Option Exercise |
0.00 |
30,397 |
0 |
216,235 |
LAUER REGAN J | Chief Accounting Officer |
Dec 15 '24 |
Option Exercise |
0.00 |
21,031 |
0 |
115,365 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):